Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Kolltan Pharmaceuticals, Inc. Snapshot 5 Kolltan Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Kolltan Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Kolltan Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Kolltan Pharmaceuticals, Inc. - Pipeline Products Glance 11 Kolltan Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Kolltan Pharmaceuticals, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Kolltan Pharmaceuticals, Inc. - Drug Profiles 14 KTN-0158 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 KTN-3379 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 KIT-SG3227 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 KTN-0182A 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibody Conjugate to Antagonize ALK Receptor for Oncology 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibody Conjugate to Inhibit Axl for Cancer, Inflammation and Infection 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibody Conjugate to Target ErbB-3 for Oncology 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibody to Inhibit c-MET for Cancer 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody to Inhibit FGFR4 for Cancer 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Monoclonal Antibody to Inhibit RON for Cancer 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Kolltan Pharmaceuticals, Inc. - Pipeline Analysis 29 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Target 29 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 30 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 31 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 32 Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates 33 Kolltan Pharmaceuticals, Inc. - Locations And Subsidiaries 36 Head Office 36 Other Locations & Subsidiaries 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38

List of Tables Kolltan Pharmaceuticals, Inc., Key Information 5 Kolltan Pharmaceuticals, Inc., Key Facts 5 Kolltan Pharmaceuticals, Inc. - Pipeline by Indication, 2016 7 Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 9 Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 10 Kolltan Pharmaceuticals, Inc. - Phase I, 2016 11 Kolltan Pharmaceuticals, Inc. - Preclinical, 2016 12 Kolltan Pharmaceuticals, Inc. - Discovery, 2016 13 Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016 29 Kolltan Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 30 Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 31 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 32 Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 33 Kolltan Pharmaceuticals, Inc., Subsidiaries 36 List of Figures Kolltan Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 7 Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 9 Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 10 Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016 29 Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 31 Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 32